Christof Vulsteke

Oncology — AZ Maria Middelares, Belgium

LeadR Profile

Christof Vulsteke AZ Maria Middelares Belgium
1 063 ScienceLeadR Reputation 1063
Network Map

Oncology

Subspecialties: Urology - Gynecology - Pharmacy

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2012 - 2026

Source: PubMed

AZ Maria Middelares

could not re-read experiences after save", error); return null; } if (persistedEntries === null) { return null; } if (persistedEntries.length === 0 && sent.some((entry) => entry.isvisible !== false)) { console.warn(" re-read after save came back empty, keeping the edited entries"); return null; } this.state.current.experience = persistedEntries; const expected = this.yearsSignature(sent); const received = this.yearsSignature(persistedEntries.map((entry) => ({ isvisible: entry.isvisible, topresent: entry.topresent, year_start: entry.startperiod, year_stop: entry.endperiod }))); if (expected !== received) { console.error(" saved experiences were not persisted as sent", { sent: expected, received: received }); return false; } return true; }, async fetchExperiences() { const response = await $.ajax({ url: ajaxLoadUserData, type: "POST", data: { security: ajaxDataLoadUserData.security, data_to_load: "OrganizationHisto", } }); const parsedData = JSON.parse(response); if (parsedData.loaded === false || !parsedData.user_data || !Array.isArray(parsedData.user_data)) { return null; } return parsedData.user_data.map((value, index) => ({ company: value["name"], url: "", position: (value.hasOwnProperty("position") ? ( value["position"] ) : ( "" ) ), startperiod: value["year_start"], endperiod: value["year_stop"], topresent: (value.hasOwnProperty("topresent") ? ( value["topresent"] ) : ( false ) ), orgid: value["orgid"], isvisible: (value.hasOwnProperty("isvisible") ? ( value["isvisible"] ) : ( true ) ), description: "", tags: [], isOpen: false, ismain: (value.hasOwnProperty("ismain") ? ( value["ismain"] ) : ( (index === 0) ? true : false ) ) })); }, async loadDataOnMount() { this.loading = true; try { const experiences = await this.fetchExperiences(); this.loadFailed = experiences === null; if (experiences !== null) { this.state.current.experience = experiences; } } catch (error) { console.warn(" could not load experiences", error); this.loadFailed = true; } this.loading = false; } }, computed: { experience: { get() { return this.state.current.experience }, }, }, async mounted() { await this.loadDataOnMount() }, } }; })

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 135

Citations

Citations: 5 389 1st author: 13 Last author: 12 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial.
research design, progression-free survival, ovary, neutropenia, neoplasms, bevacizumab, drug therapy, maintenance, drug-related side effects and adverse reactions, ovarian neoplasms, response evaluation criteria in solid tumors, therapeutics, carcinoma, ovarian epithelial, chemotherapy
Lancet Oncol Top journal20260
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. Reply.
urinary bladder, urinary bladder neoplasms, neoplasms
N Engl J Med Top journal20260
TKI-associated proteinuria and nephrotic syndrome: a narrative review with clinical illustration in radio-iodine-refractory thyroid cancer.
proteinuria, neoplasms, thyroid gland, nephrotic syndrome, thyroid neoplasms, therapeutics
Acta Clin Belg20260
PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer.
genes, recombination, genetic, homologous recombination, progression-free survival, anemia, androgens, neoplasms, prostate, drug-related side effects and adverse reactions, recombinational dna repair, prostatic neoplasms
N Engl J Med Top journal20260
Clinical Trial Protocol for ProBio-mHSPC: A ctDNA-driven De-escalation and Intensification Platform Trial for Metastatic Hormone-sensitive Prostate Cancer.
clinical protocols, urology, neoplasms, prostate, biomarkers, hormones, prostatic neoplasms, therapeutics
Eur Urol Focus20260

Clinical Studies 34

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 24
Phase 2 5
N/A 2
Phase 2/Phase 3 2
Phase 1 1

By status:

Completed 13
Recruiting 10
Active not recruiting 9
Terminated 2

By type:

Interventional 33
Observational 1

By Monocentric/Multicentric:

monocentric 1
multicentric2to4 1
multicentric5to9 0
multicentricup10 32

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

5 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK 2870 021)
2023-508047-40-00 — ovary, neoplasms, bevacizumab, drug therapy, maintenance, ovarian neoplasms, therapeutics, chemotherapy
Phase 3Recruiting2026
A clinical study of sacituzumab tirumotecan and pembrolizumab in people with endometrial cancer (MK 2870 033)
2024-519331-42-00 — dna mismatch repair, safety, neoplasms, maintenance, respect, therapeutics, endometrial neoplasms, carcinoma
Phase 3Recruiting2025
Pasritamig vs Placebo in late line Metastatic Castration resistant Prostate Cancer (mCRPC)
2025-520927-26-00 — cells, kallikreins, neoplasms, prostate, prostatic neoplasms, castration, t-lymphocytes
Phase 3Recruiting2025
A clinical trial of sacituzumab tirumotecan to treat urothelial cancer (MK 2870 031)
2024-520014-22-00 — neoplasms, drug therapy, chemotherapy, carcinoma
Phase 3Recruiting2026
A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab vs Chemotherapy plus Pembrolizumab as First Line Treatment of HER2 Expressing (IHC 3 2 ) Mismatch Repair Proficient (pMMR) Endometrial Cancer
2023-508056-19-00 — dna mismatch repair, neoplasms, drug therapy, therapeutics, trastuzumab, endometrial neoplasms, chemotherapy
Phase 3Recruiting2025

LeadR Networks

Main global connection map